Tvardi Therapeutics, Inc. (NASDAQ:TVRD) — Market Cap & Net Worth
Market Cap & Net Worth: Tvardi Therapeutics, Inc. (TVRD)
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has a market capitalization of $24.20 Million ($24.20 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #24520 globally and #5188 in its home market, demonstrating a -7.19% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tvardi Therapeutics, Inc.'s stock price $2.58 by its total outstanding shares 9381344 (9.38 Million). Review Tvardi Therapeutics, Inc. (TVRD) total liabilities to assess the company's total debt and financial obligations.
Tvardi Therapeutics, Inc. Market Cap History: 2025 to 2026
Tvardi Therapeutics, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $40.34 Million to $24.20 Million (0.00% CAGR).
Tvardi Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tvardi Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TVRD by Market Capitalization
Companies near Tvardi Therapeutics, Inc. in the global market cap rankings as of June 18, 2026.
Key companies related to Tvardi Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
Tvardi Therapeutics, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Tvardi Therapeutics, Inc.'s market cap moved from $40.34 Million to $ 24.20 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $24.20 Million | -40.00% |
| 2025 | $40.34 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Tvardi Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.20 Million USD |
| MoneyControl | $24.20 Million USD |
| MarketWatch | $24.20 Million USD |
| marketcap.company | $24.20 Million USD |
| Reuters | $24.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical d… Read more